iii) BTK inhibitors in 16 h ZIP model
Male C57BL/6 mice (10-12 weeks old) were pre-treated with ONO-4059,
CNX-774, Olmutinib, LFM-A13, and Acalabrutinib (1
mg·kg-1; p.o.) or vehicle (5% DMSO, 30%
cyclodextrin) one hour prior to zymosan challenge (100 ug; i.p.).
Compounds where all purchased from SellectChem, as selected because they
had varying properties compared to ibrutinib i.e. more selective
acalabrutinib, not marketed as a BTK inhibitor but target BTL Olmutinib,
more potent ONO-4059 than ibrutinib and structurally different to
ibrutinib CNX-774. All compounds also have publication history of being
bioactive following oral gavage. Blood was collected by direct cardiac
puncture and peritoneal exudate cells were harvested in ice-cold cell
PEC harvest buffer (PBS, 5 mM EDTA) 16 h after zymosan challenge.